Enable the 'export of EU APIcertification documents' and 'pharmaceutical export salescertificate' electronic proof
Since December 1, 2022, the official launchof the "export of EU API certification documents" and"pharmaceutical export sales certificate" electronic proof, therelevant matters are announced as follows.
First, since December 1, 2022, theissuance of "export of EU API documents" and "drug export salescertificate" to enable electronic proof. Electronic proof and paper proofhas the same effect.
Second, combined with China'spharmaceutical export practices and the latest WHO guidelines, the new templatefor the export of pharmaceutical products sales certificate (see annex). SinceDecember 1, 2022, the provincial drug regulatory authorities should be issuedin accordance with the updated template "drug export sales certificate.
Third, do a good job to enable theelectronic proof of publicity and guidance. The use of the State DrugAdministration application system issued by the electronic certificate, theapplicant must first register in the State Drug Administration online officehall and real name authentication, enter the online office hall corporate space"my license" section, you can also log in the "China DrugAdministration APP". View and download the corresponding electroniccertificate. Applicants should be properly stored electronic proof. State DrugAdministration issued by the electronic certificate of frequently askedquestions and answers, see the State Drug Administration online office hallelectronic license help section.
Fourth, the use of the provincialapplication system issued by the electronic certificate, the provincial drugregulatory authorities should be clear to the administrative region of thebusiness guidelines, guidance and services.
Notice is hereby given.
State Drug Administration
2026-08-21
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
Biocytogen announces the launch of the 'Nano 100 Project' to develop fully human therapeutic nanobodies against 100+ targets
-
Wantai Biotech 20-valent pneumonia vaccine started clinical trials, how far is domestic substitution?
-
Yiming Cell 'Suspension 293XS Cell Bank' completed DMF filing with the US FDA
-
The phase III clinical study of Junshi Biologics in combination with teripulimab in the treatment of advanced triple-negative breast cancer reached the primary endpoint
-
The next bombshell: 'PD-1 + ADC', Kelun, Hengrui are going to win numbness?
-
L-Rotator Biotech completed its pre-A financing and continued to increase its investment in the CGT field
-
Hainan to promote drug import facilitation
-
China to focus on building quality and efficient TCM service system in next five years
-
Overwhelming influx of alliance procurement: orthopaedics and IOLs
Recommend Reading
-
EAEU Initiates Review of Anti-Dumping Measures on Chinese Titanium Dioxide, Suspends Duties During Investigation
-
FDA Tracks Industry Dye Removal
-
G20 Pushes Fertilizer Access as Food-Security Risk Rises
-
Sudden Turmoil in Middle East Shipping Routes: Multiple Carriers Announce Emergency Navigation and Surcharge Policies
-
Syngenta Caught in Trade Crossfire
-
Uses and Properties of 3-Methyl-1-Butanol
-
Key Reactions and Uses of Lithium Aluminum Hydride
-
Premium Global Chemical Sourcing Requests (8-12 Dec 2025)
-
Chemical Properties and Applications of Cyclopropen
-
Business Society’s Market Outlook for Maleic Anhydride on August 13, 2026: Decline